相关实验视频

Updated: Aug 9, 2026

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

对ESYT3在肺腺癌中的预后值和免疫影响的全面分析

Xuedong Li¹, Jianlin Chen^2,3, Jie Meng¹

¹Medical Science Laboratory, Liuzhou Worker's Hospital, Liuzhou, Guangxi, China.

|September 1, 2023

概括

该研究发现,ESYT3在肺腺癌 (LUAD) 中是下调的,与较差的患者结果和晚期疾病相相关. 低ESYT3表达表明它可能是LUAD的预后标志物和治疗点.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
基因组学就是基因组学.

背景情况:

关于ESYT3与瘤发育之间的关联,研究有限.
了解肺腺癌 (LUAD) 新型分子标志物对于改善患者预后至关重要.

研究的目的:

研究ESYT3在肺腺癌 (LUAD) 中的分子特性.
为了评估ESYT3在LUAD患者的预后价值.
探索ESYT3,基因共同表达,免疫透和LUAD中的甲基化之间的关系.

主要方法:

使用TCGA,GEPIA,UALCAN和KM Plotter数据库进行表达和生存分析.
雇员cBioPortal和Metascape用于共同表达和丰富分析.
使用TIMER2研究免疫细胞透和使用MethSurv进行甲基化.

主要成果:

在LUAD组织中,ESYT3 mRNA表达显著下调.
低ESYT3表达与先进的N和阶段分类相关,并预测了低生存率.
同表达的基因在细胞分裂途径中得到丰富;ESYT3与免疫透和检查点有相关性.
低甲基化与低ESYT3表达和LUAD的不良预后有关.

结论:

在肺腺癌中,ESYT3 功能作为潜在的预后生物标志物.
ESYT3可能是LUAD治疗的有前途的治疗标.

更多相关视频

Development of Compendium for Esophageal Squamous Cell Carcinoma

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...